Quick Takeaways
- BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A for Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share (AVTX).
- Disclosed ownership: 10%.
- Date of event: 31 Dec 2025.
Quoteable Key Fact
"BIOTECHNOLOGY VALUE FUND L P disclosed 10% ownership in Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share (AVTX) on 31 Dec 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 6.8% | 1,286,909 | 0 | 1,286,909 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF I GP LLC | 6.8% | 1,286,909 | 0 | 1,286,909 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BIOTECHNOLOGY VALUE FUND II LP | 2.7% | 500,507 | 0 | 500,507 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF II GP LLC | 2.7% | 500,507 | 0 | 500,507 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| Biotechnology Value Trading Fund OS LP | 0.5% | 97,524 | 0 | 97,524 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF Partners OS Ltd. | 0.5% | 97,524 | 0 | 97,524 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF GP HOLDINGS LLC | 9.4% | 1,787,416 | 0 | 1,787,416 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF PARTNERS L P/IL | 10% | 1,904,257 | 0 | 1,904,257 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF INC/IL | 10% | 1,904,257 | 0 | 1,904,257 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| LAMPERT MARK N | 10% | 1,904,257 | 0 | 1,904,257 | /s/ Mark N. Lampert | Mark N. Lampert |